NCT01073696已完成1 期
A Phase I Study to Evaluate the Effect of External Heat on the Pharmacokinetics of a Transdermal Granisetron Patch in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- Pharmacokinetic profile of the granisetron patch in healthy subjects when heat is applied
研究概览
简要总结
The purpose of this study is to determine the effect of heat applied to a granisetron transdermal patch in healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male or female subjects aged ≥ 18 and ≤ 45 years at screening. Subjects must demonstrate understanding of the purposes and risks of the study and agree to follow the restrictions and schedule of study procedures, as evidenced by voluntary written informed consent (signed and dated) obtained before taking part in any trial-related activities.
排除标准
- •Any current or previous disease, disorder, allergy or condition (including recent unexplained weight loss) that could affect the study conduct or laboratory assessments, or that presents undue risk from the study medication or procedures. Hypersensitivity to adhesive plasters or surgical tape.
- •Any physical examination or screening investigation result that indicates the subject is unfit for the study.
- •Scarring on upper arms, including extensive tattoos making skin reactions unevaluable.
- •A positive virology test, urine test for drugs of abuse, or pregnancy test result (females of childbearing potential only).
- •Recent use of prescribed or over-the-counter medication that, in the opinion of the Investigator or the Sponsor, will interfere with the study procedures or compromise safety.
- •Received an investigational drug within 3 months (90 days) preceding patch application.
- •Loss of ≥ 400 mL of blood (e.g. been a blood donor) within the past 3 months.
- •Average weekly alcohol consumption of greater than 21 units (males) or 14 units (females), or habitually smokes ≥ 5 cigarettes or equivalent tobacco per day within the 6 months before patch application. Subjects may not smoke while confined to the study site. Subjects must not consume alcohol, or xanthine-containing foods or drinks within 48 hours prior to dosing until discharge.
- •Lactating female subjects, and female subjects of childbearing potential who are not willing to use an acceptable form of contraception from the screening visit, during the study and for 90 days after the study.
- •Employee of the Investigator or study centre, with direct involvement in the proposed study or other studies under the direction of that Investigator or study centre, as well as family members of the employees or the Investigator.
研究组 & 干预措施
granisetron IV
Active Comparator
干预措施: granisetron IV (Drug)
granisetron patch
Experimental
干预措施: granisetron patch (Drug)
结局指标
主要结局
Pharmacokinetic profile of the granisetron patch in healthy subjects when heat is applied
时间窗: 0 - 196 hours post dose
To assess the effect of locally applied heat on the pharmacokinetic profile of granisetron delivered from the patch. Subjects will be randomized to receive Treatment A Sancuso patch ONLY and Treatment B, Sancuso PLUS Cura-Heat pad. Sancuso will be worn by the subjects for 5 days continuously. The Cura-Heat pad will be applied over the patch for 4.5 hours on each of the 5 days. During these 5 days PK sampling is planned to measure the initial release of granisetron from the patch and cover the predicted maximum observed concentrations with or without the Cura-Heat pad in place.
次要结局
- Safety and tolerability assessment(Up to 23 days post dose)
- residual granisetron after patch use in healthy subjects(120 hours post dose)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Granisetron Transdermal Patch for Prevention of Postoperative Nausea and VomitingPostoperative Nausea and VomitingNCT02457195Milton S. Hershey Medical Center50
撤回
4 期
The Evaluation of External Thermomechanical Stimulation for Pain Reduction in Patients Undergoing Nail InjectionNail DiseasesNCT04422795Weill Medical College of Cornell University
已完成
不适用
Probe Configuration and Time-Temperature Dose Ranging for Understanding of Skin Lesion EffectsHistological Response of Tissue to ColdNCT01681745Pacira Pharmaceuticals, Inc30
进行中（未招募）
1 期
Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)Glioblastoma, AdultNCT03277638Case Comprehensive Cancer Center32
已完成
1 期
Extracorporeal Immune Support System (EISS) for the Treatment of Septic PatientsSevere Sepsis and Septic ShockNCT00818597University of Rostock10